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Abstract
We previously demonstrated the ability of HIV-1 Vpr protein to activate the oxidative stress pathway, thus leading
to the induction of the hypoxia inducible factor 1 alpha (HIF-1a). Therefore, we sought to examine the interplay
between the two proteins and the impact of HIF-1a activation on HIV-1 transcription. Using transient transfection
assays, we identified the optimal concentration of HIF-1a necessary for the activation of the HIV-1 promoter as well
as the domain within HIF-1a responsible for this activation. Our findings indicated that activation of the HIV-1 LTR
by Vpr is HIF-1a dependent. Furthermore, we showed that both Vpr and HIF-1a activate the HIV-1 promoter
through the GC-rich binding domain within the LTR. Taken together, these data shed more light on the
mechanisms used by Vpr to activate the HIV-1 promoter and placed HIF-1a as a major participant in this activation.
Introduction
The HIV-1 accessory protein viral protein R (Vpr) is
synthesized late in the HIV-1 life cycle, packaged into
the virion, and is essential for HIV-1 replication in
macrophages [1]. The infected macrophages have been
shown to release Vpr, which affects neuronal growth
and plasticity [2]. Studies from several groups have
demonstrated that Vpr mediates multiple functions,
including nuclear import of the HIV-1 pre-integration
complex [3], G2 cell cycle arrest, transactivation of both
viral replication and host genes and induction of apop-
tosis [4]. Most of these Vpr functions have been con-
firmed in an in vitro system. However, the physiological
effect of Vpr in vivo, especially in neurons as well as its
concentration [5], remains to be identified. Vpr was also
detected in a soluble form in Cerebrospinal fluid (CSF)
and sera of HIV-1-infected patients displaying neurolo-
gical disorders [2]. Vpr was shown to activate the pro-
duction and accumulation of the reactive oxygen species
(ROS), a phenomenon that led to the activation of the
hypoxia inducible factor 1 alpha (HIF-1a) [6].
Reactive oxygen species (ROS), especially superoxide
anions (O2
-) and hydrogen peroxide (H2O2), have been
shown to promote HIF-1a protein accumulation in vitro
and in vivo [7]. ROS also play an important role in the
pathophysiology of many diseases such as atherosclero-
sis, tumor progression, Alzheimer’s disease, Parkinson’s
disease, and amyotrophic lateral sclerosis [8-10].
Hypoxia on the other hand, has been shown to be a key
component of the tumor microenvironment, causing
genetic instability by affecting the DNA repair capacity
of tumor cells [11]. Hypoxia is also known to increase
angiogenesis, to up regulate glycolytic enzymes and to
provide selective pressure for cancer cell-survival [12].
HIF-1 is a heterodimeric-transcription factor consist-
ing of two distinct components, the oxygen-sensitive a
subunit (HIF-1a) and constitutively expressed b subunit
[HIF-1b, also known as the acryl hydrocarbon receptor
nuclear translocator (ARNT)], both of which are mem-
bers of the PAS (Per/ARNT/Sim) protein family [13,14].
HIF-1a binds to HIF-1b and induces hypoxic gene
expression [15]. Under normoxic conditions, HIF-1a
protein is barely detectable because it is rapidly decayed.
The HIF-1a structural features and their known biologi-
cal functions are as follows: The N-terminal domain of
HIF-1a contains a basic helix-loop-helix domain and a
PAS domain that are essential for dimerization with
HIF-1b and binding to the conserved HIF-response ele-
ment (HRE) DNA sequence (5’-RCGTG-3’) [16]. The C-
terminal domain of HIF-1a contains several regulatory
domains responsible for oxygen-dependent gene expres-
sion. These include two separate transactivation
domains, N-TAD (N-terminal transactivation domain;
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residues 531-575) and C-TAD (C-terminal transactiva-
tion domain; residues 786-826), which bind general
transcriptional co activators such as CBP/p300, SRC-1,
and TIF-2 [17]. Two transactivation domains flank an
inhibitory domain (residues 576- 785), and a nuclear
localization signal, located at both N-and C-terminal
domains (residues 17-74 and residues 718-721, respec-
tively). The oxygen dependent destruction domain
(ODD, residues 401-603) is a critical component of
HIF-1a and is involved in HIF-1a protein stability. The
ODD contains two PEST-like motifs at residues 499-518
and 581-600, which may also regulate HIF-1a protein
degradation.
In this manuscript, we demonstrated the presence of a
functional interplay between Vpr and HIF-1a leading to
the activation of the LTR. Further, our findings indicate
that Vpr’s ability to activate the LTR is HIF-1a
dependent.
Results and discussion
First, we sought to identify the optimal concentration of
HIF-1a needed for the activation of the HIV-1 promo-
ter. Human kidney cells, 786-O, which do not express
endogenous HIF-1a [18] (1 × 105) were transfected with
a reporter plasmid containing the LTR upstream
regulatory sequence fused to luciferase reporter gene
(0.1 μg) together with an increasing concentration of
HIF-1a. Twenty-four hours post transfection, the cells
were washed and processed for luciferase assay. As
shown in Figure 1A, 0.5 μg of HIF-1a was the optimal
concentration to activate the LTR.
Activation of the LTR by HIF-1a provided us with
the rationale to identify the cis-element within the
LTR responsible for this activation. 786-O cells were
transfected with 0.5 μg of HIF-1a expression plasmid
together with reporter plasmids containing the LTR
full length or its deletion mutants where the B or
the GC-rich motifs were removed, respectively. These
motifs were shown to be the binding sites for NF-B
and Sp1 transcription factors. As shown in Figure 1B,
HIF-1a activates the LTR and its mutant derivative
(LTR-ΔB), however the activation was altered when
the GC-rich motif was removed. The HIV-1 LTR has
been shown to contain three GC-rich motifs localized
between positions -78 and -42 [19]. Our findings led
us to conclude that HIF-1a activates the LTR
through the GC-rich motif. Interestingly, several fac-
tors have been also shown to activate the HIV-1 LTR
through their interplay with Sp1 including the HIV-1
Vpr [20].
Figure 1 Effect of HIF-1a on HIV-1 LTR. A and B. 786-O cells were transfected with 0.1 μg of the LTR-Luc full length or deletion mutants
along with an increasing concentration of HIF-1a (A) or 0.5 μg of HIF-1a (B). The amount of DNA in each transfection mixture was normalized
with pcDNA6HisA. Luciferase activity was determined 48 hours after transfection. Results are displayed as histograms. C. Approximately 100, 000
cpm of synthetic [g32P]-labeled double-stranded DNA oligonucleotide probe corresponding to the HIV-1 LTR GC-rich site was incubated with 10
μg of nuclear extracts prepared from microglial cells transfected with c-myc-HIF-1a. Labeled probe was also incubated with nuclear extracts
prepared from pcDNA-transfected microglial cells in the presence of a specific DNA competitor (cold probe, lane 3), non-specific competitor (an
unrelated dsDNA) (lane 4), anti-c-myc antibody (lane 6) and normal mouse serum (NMS) (lane 5).
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Since HIF-1a activates the HIV-1 LTR, we next inves-
tigated that potential mechanism involved in such acti-
vation. Therefore, we examined if HIF-1a can activate
the LTR directly since the LTR contains a predicted
HRE located between -71 and -67 [RCGTG, where R
could be an A or G]. We performed gel shift assays
using nuclear extracts derived from microglia, which we
transfected with 5 μg c-myc-HIF-1a expression plas-
mids. Ten micrograms of nuclear extract prepared from
microglial cells were incubated with labeled GC-rich
dsDNA primer spanning nucleotides -82 to -61. As
shown in Figure 1C, the intensity of the band corre-
sponding to the DNA-HIF-1a complex was enhanced in
cells transfected with a plasmid expressing HIF-1a
(complex C1 in lane 2). To examine whether HIF-1a
protein formed complex C1, we performed super shift
experiment (lanes 5 and 6). The presence of the HIF-1a
protein in complex C1 was demonstrated, as the addi-
tion of anti-c-myc antibody (lane 6), but not a non-
immune serum (lane 5), led to an up-shift of the com-
plex and the formation of a new complex, C2. Anti-c-
myc antibodies were unable to abolish binding of the
complex C1 to the DNA completely, which led us to
conclude that, in addition to HIF-1a, other proteins
such as Sp1 are present in the C1 complex (lane 6).
Competition using unlabelled wild type or mutant DNA
probes verified the specificity of the complex (lanes 3
and 4).
Previously, we demonstrated the ability of Vpr to
modulate HIV-1 LTR transcription through its potential
binding to the Sp1 transcription factor in the GC-rich
region within the LTR [20]. To assess the effect of Vpr
and/or Sp1 on transcription of the HIV-1 LTR in the
presence and absence of HIF-1a, 786-O cells were
transfected with 0.1 μg of LTR-luc together with 0.1 μg
of Vpr expression plasmid in the presence of an increas-
ing concentration of HIF-1a expression plasmid (0.25,
0.5 and 1.0 μg). As shown in Figure 2A, addition of
HIF-1a did not affect the ability of Vpr to activate the
LTR. Note that these cells do not express endogenous
HIF-1a.
Reciprocally, we investigated the impact of an increas-
ing concentration of Vpr on HIF-1a ability to activate
the LTR. 786-O cells were transfected with a reporter
plasmid containing the LTR upstream regulatory
sequence fused to a reporter gene together with 0.5 μg
plasmids expressing HIF-1a and/or increasing amount
of Vpr. 786-O cells do not express endogenous HIF-1a
[18]. As shown in Figure 2B, Vpr activates the LTR by
3-4 fold in the absence of HIF-1a. This activation was
additively enhanced when 0.1 μg of Vpr and 0.5 μg of
HIF-1a were co-expressed. Interestingly, activation of
the HIV-1 promoter decreases when 0.8 μg of Vpr and
0.5 μg of HIF-1a plasmids were co-expressed leading to
the conclusion that both proteins may be competing for
Sp1 or LTR DNA interaction.
To further test this hypothesis, we performed gel shift
assay using nuclear extracts from microglial cells, which
we transfected with 5 μg of Vpr expression plasmids. Ten
micrograms of nuclear extract prepared from the cells
were incubated with labeled GC-rich dsDNA primer
spanning nucleotides -82 to -61. As shown in Figure 2C,
the intensity of the band corresponding to the DNA-Vpr
complex was enhanced in cells transfected with a plasmid
expressing Vpr (complex C1 in lane 2). To examine
whether Vpr protein formed or was a part of complex
C1, we performed super shift experiment (lanes 3 and 4).
The presence of the Vpr protein in complex C1 was
demonstrated, as the addition of anti-Vpr antibodies
(lane 4), but not the addition of a non-immune serum
(lane 3), led to an up-shift of the complex and the forma-
tion of a new complex, C2. Anti-Vpr antibodies were
able to abolish binding of the complex C1 to the DNA
completely, which led us to conclude that Vpr is the
main protein present in the C1 complex (lane 4).
Finally, we examined whether Vpr and HIF-1a com-
pete for Sp1 or LTR-DNA binding in transfection assays
where we increased the concentration of Sp1. 786-O
cells were transfected with LTR-luc in the presence and
absence of constant amount of Vpr and/or HIF-1a
expression plasmids along with an increasing concentra-
tion of Sp1 plasmid (0.25, 0.5 and 1.0 μg). As shown in
Figure 2D, increasing amount of Sp1 plasmid had little
or no effect on activation of the LTR by Vpr and/or
HIF-1a when compared to the control.
Next, we sought to identify the domain within HIF-
1a responsible for HIV-1 LTR activation and interplay
with Vpr. First, we examined the optimal concentra-
tion used by these mutants to activate the LTR and
found that 0.5 μg of expression plasmids yielded the
best activation (Figure 3B). Interestingly, we found that
the region located between the 2 PEST domains that
correspond to the N-transactivating domain of the
HIF-1a protein may be the region responsible for the
LTR activation.
To confirm this observation, we created a new dele-
tion mutant of HIF-1a in which the N-TAD domain
was deleted (Figure 3A). 786-O cells were transfected
with 0.1 μg of the LTR-luc along with 0.5 μg of HIF-1
deletion mutant (ΔN-TAD). Twenty-four hours later,
transfection was terminated and the cells were washed
and processed for luciferase assay. As shown in Figure
3C, HIF-1a mutant modestly activated the LTR leading
to the conclusion that additional domain(s) located in
the N-terminal region of the HIF-1a may be involved in
the LTR activation. The sub-cellular localization of HIF-
1a mutants was also determined using immunocyto-
chemsitry, and HIF-1a (full length and mutant)
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localized to the nucleus as well as the cytoplasm of the
cells (HIF-1a [1-531]) (Figure 3D).
The functional interplay between Vpr and HIF-1a as
well as the identification of the potential domain within
HIF-1a responsible for activation of the LTR prompted
us to examine the relation between Vpr and HIF-1a
deletion mutants and their interplay in cells that lack
HIF-1a. To that end, microglial cells were transfected
with 0.1 μg of the LTR-luc along with 0.1 μg of Vpr and
or 0.5 μg of HIF-1a (wt and deletion mutants) expres-
sion plasmids.
Twenty-four hours later, the cells were collected
and processed for luciferase assay. Interestingly, while
a modest additive activation of the LTR was observed
in the presence of Vpr and full length HIF-1a (Figure
4A, lane 3), a significant additive effect was observed
when Vpr was co-expressed along with HIF-1a
mutants (lanes 4 and 5). Expectedly, HIF-1a mutant
(1-531) did not affect the ability of Vpr to activate the
LTR (lane 6).
A similar experiment was repeated using 786-O cells
(HIF-1a-/-) and the results are displayed in lanes 7-12.
Surprisingly, Vpr failed to activate the LTR in the
absence of endogenous HIF-1a (lane 8). This activation
was restored when Vpr was co-expressed with HIF-1a
full length or deletion mutants (lanes 9-12). As
expected, HIF-1a mutant (1-531), lacking both C-TAD
and N-TAD did not affect the ability of Vpr to activate
Figure 2 Functional interplay between HIV-1 Vpr and HIF-1a. A and B. 786-O cells were transfected with LTR-Luc full length along with an
increasing concentration of HIF-1a (A) and/or Vpr (B) expression plasmids. The amount of DNA in each transfection mixture was normalized
with pcDNA6HisA. Luciferase activity was determined 48 hours after transfection. Results are displayed as histograms. C. Approximately 100, 000
cpm of synthetic [g32P]-labeled double-stranded DNA oligonucleotide probe corresponding to the HIV-1 LTR GC-rich site was incubated with 10
μg of nuclear extracts prepared from microglial cells transfected with Vpr expression plasmid. Labeled probe was also incubated with nuclear
extracts prepared from pcDNA-transfected microglial cells in the presence of anti-Vpr antibody (lane 4) and normal mouse serum (NMS) (lane 2).
D. To further examine the interplay between Vpr and HIF-1a, 786-O cells were transfected with LTR-Luc along with HIF-1a, Vpr and/or Sp1 using
different combinations as shown. Luciferase activity was determined 48 hours after transfection. Results are displayed as histogram. Each
transfection was repeated 3 times using different DNA preps.
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the LTR (lane 12). These results led us to conclude that
Vpr requires a minimum presence of the HIF-1a in
order to activate the HIV-1 LTR.
There is growing evidence that oxidative stress occurs
in the brains of HIV-infected patients, and this can be
one of the causes of progressive multiple symptoms of
motor and cognitive dysfunction, and changes that char-
acterize the AIDS dementia complex. Oxidative stress
combined with activation of the inflammatory process
plays a crucial role in disease progression in HIV-
infected individuals. The complications in patients with
AIDS are frequently a result of enhanced formation of
many free radical species and the deregulation of endo-
genous antioxidant moieties. This suggests that,
although essential for life, ubiquitous oxygen is also, by
its products of metabolism, toxic to cells.
In this regard, HIF-1a was shown to be activated dur-
ing cell stress and that this activation leads to its stabili-
zation and activation of specific genes. The role of HIF-
1a in cells infected with HIV-1 was unclear which pro-
vided us with the rationale to explore this role. To that
end, we previously reported, that HIV-1 Vpr protein has
the ability to promote stress in microglial cells leading
to HIF-1a activation [6]. We also showed that activation
of HIF-1a by Vpr leads to positive regulation of the
LTR. Therefore, in this paper, we sought to examine the
impact of HIF-1a up-regulation by Vpr on the HIV-1
promoter and Vpr functions. Interestingly, we demon-
strated that Vpr activates the HIV-1 promoter through
its functional interplay with HIF-1a and that this activa-
tion is lost in the absence of endogenous HIF-1a. Our
data further confirm the need of Vpr to activate HIF-1a
independently of the reactive oxygen species as we pre-
viously demonstrated [6]. It also point to the major role
that HIF-1a plays during the regulation of the HIV-1
promoter.
These results led to the conclusion that HIF-1a might
be playing the same role as APOBEC [21] and that will
keep HIV-1 Vpr and Vif proteins, respectively, under
control; a phenomenon that needs to be further studied
in order to develop a Vpr inhibitor.
Methods
Plasmids
The HIF-1a plasmid (1-826) was previously described,
while its deletion mutants (1/786; 1/600 and 1/531)
were cloned using the following primers: (coding) 5’-
ctggttggatccgccaccatggagggcgccggcggcgcg-3’ (BamHI);
(non coding) 786: 5’-aaccagatgcggccgctcttgccccagcagtc-
taca-3’; 600: 5’- aaccagatgcggccgctcaa ctgtgctttgaggact-5’;
531:5’-aaccagatgcggccgctcattgaccatatcactatc-3’ (NotI). Full
length HIF-1a c-DNA was used as a template. The new
Figure 3 Identification of the HIF-1a domain responsible for the LTR activation. A. Schematic representation of the structural organization
of the HIF-1a domains. B and C. 786-O cells were transfected with LTR-Luc along with HIF-1a full length and deletion mutant expression
plasmids. The amount of DNA in each transfection mixture was normalized with pcDNA6HisA. Luciferase activity was determined 48 hours after
transfection. Results are displayed as histograms. Each transfection was performed 3 times using different DNA prep. D. Subcellular localization of
HIF-1a. 786-O cells were transfected with c-myc-HIF-1a FL or deletion mutants as described in Methods section. Both proteins were detected in
the nucleus and the cytoplasm (HIF-1a [1-531]) of the cells.
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products were cloned in-frame with Myc-His tag of
pcDNA-6A plasmid. The internal deletion of N-terminal
transactivation domain (Δ NTAD) was performed as
previously described (Imai et al., 1991). Briefly, identifi-
cation of the recombinant clone was done using a
unique restriction site NheI, which was introduced in
the place of deletion. The primers used were; (coding:
573/583) 5’- cgttccttcgatcagttgt cacca-3’ and (non cod-
ing: 523/531) 5’-gctagcttcattgaccatatcactatccac-3’ (NheI).
The HIV-1 LTR and its deletion mutants as well as
pcDNA3-Vpr (wt and mutant) and CMV- Sp1 plasmids
were previously described [22,23].
Cell Culture, and Transfection Assays
Human kidney (HIF-1a-/- known as 786-O) [purchased
from ATCC] and microglial cell lines were maintained
in DMEM + 10% FBS. Cells were transfected with 0.1
μg of reporter plasmid (LTR-Luc) or co-transfected with
0.1-0.8 μg of Vpr or 0.5 μg of HIF-1a (wt or deletion
mutants) expression cDNA. The amount of DNA used
for each transfection was normalized with pcDNA3 vec-
tor plasmid. Each transfection was repeated multiple
times with different plasmid preparations. Cell extracts
were prepared 24 h after transfection, and Luciferase
assay was performed as previously described [6].
Gel electrophoresis mobility-shift assay (EMSA)
A gel electrophoresis mobility-shift assay was performed
as described previously [22]. Oligonucleotides corre-
sponding to the HIV-1 LTR promoter region were
synthesized, annealed, labeled with [g-32P] ATP and
incubated at 4°C for 30 min with 10 μg nuclear extracts.
For super shift assays, antibodies directed against Vpr
were mixed with nuclear proteins for 1 h at 4°C prior to
addition of the probe. The sequences of the oligonucleo-
tides used in these experiments were 5’-tcccagg-
gaggcgtggcctgg-3’ (-82/-61) and 5’-ccaggccacgcctccct-3’
(-61/-82).
Immunocytochemistry
786-O cells were transfected with 1 μg of c-myc-HIF-1a
full length or deletion mutant expression plasmids and
seeded in poly-L-lysine-coated glass chamber slides.
Cells were fixed in 4% paraformaldehyde, blocked with
5% normal horse serum in PBS-BSA 0.1% for 2 hrs and
then incubated with anti-HIF-1a mouse (BD Bioscience)
primary antibody over night. For HIF-1a mutant (1-
531), anti-myc mouse primary antibody was used. Cells
were then washed and incubated with FITC-conjugated
anti-mouse secondary antibody for 1 hr. Expression of
HIF-1a (FL and mutants) was visualized by fluorescence
microscopy.
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